These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 9745778

  • 1. The effect of live measles vaccines on serum vitamin A levels in healthy children.
    Yalçin SS, Yurdakök K, Ozalp I, Coşkun T.
    Acta Paediatr Jpn; 1998 Aug; 40(4):345-9. PubMed ID: 9745778
    [Abstract] [Full Text] [Related]

  • 2. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
    Samoĭlovich EO, Kapustik LA, Fel'dman EV, Ermolovich MA, Svirchevskaia EIu, Titov LP, Zakharenko DF, Belova EIu, Chernovetskiĭ MA, Korostik TS.
    Zh Mikrobiol Epidemiol Immunobiol; 1998 Aug; (4):36-40. PubMed ID: 9783398
    [Abstract] [Full Text] [Related]

  • 3. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH, Saracen CL, Peter G.
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [Abstract] [Full Text] [Related]

  • 4. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R.
    Pediatr Infect Dis J; 1999 Jan; 18(1):42-8. PubMed ID: 9951979
    [Abstract] [Full Text] [Related]

  • 5. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.
    Boulianne N, De Serres G, Ratnam S, Ward BJ, Joly JR, Duval B.
    Vaccine; 1995 Nov; 13(16):1611-6. PubMed ID: 8578850
    [Abstract] [Full Text] [Related]

  • 6. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G, Peña B, Marimón JM, Pérez-Trallero E.
    Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
    [Abstract] [Full Text] [Related]

  • 7. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
    Miller E, Hill A, Morgan-Capner P, Forsey T, Rush M.
    Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
    Just M, Berger R, Just V.
    Dev Biol Stand; 1986 Jun; 65():85-8. PubMed ID: 3030863
    [Abstract] [Full Text] [Related]

  • 9. Seroconversion of a trivalent measles, mumps, and rubella vaccine in children aged 9 and 15 months.
    Forleo-Neto E, Carvalho ES, Fuentes IC, Precivale MS, Forleo LH, Farhat CK.
    Vaccine; 1997 Dec; 15(17-18):1898-901. PubMed ID: 9413099
    [Abstract] [Full Text] [Related]

  • 10. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age.
    Klinge J, Lugauer S, Korn K, Heininger U, Stehr K.
    Vaccine; 2000 Jul 15; 18(27):3134-40. PubMed ID: 10856793
    [Abstract] [Full Text] [Related]

  • 11. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.
    White CJ, Stinson D, Staehle B, Cho I, Matthews H, Ngai A, Keller P, Eiden J, Kuter B.
    Clin Infect Dis; 1997 May 15; 24(5):925-31. PubMed ID: 9142794
    [Abstract] [Full Text] [Related]

  • 12. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE, Markowitz LE, Heath J, Redd SC, Coleman S, Bellini WJ, Sievert A.
    JAMA; 1996 Mar 06; 275(9):704-7. PubMed ID: 8594268
    [Abstract] [Full Text] [Related]

  • 13. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR.
    Pediatr Infect Dis J; 1996 Aug 06; 15(8):687-92. PubMed ID: 8858673
    [Abstract] [Full Text] [Related]

  • 14. Response to measles-mumps-rubella vaccine in children on dialysis.
    Schulman SL, Deforest A, Kaiser BA, Polinsky MS, Baluarte HJ.
    Pediatr Nephrol; 1992 Mar 06; 6(2):187-9. PubMed ID: 1571219
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
    Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G, Linde A, Ringdén O, Wahren B.
    J Infect Dis; 1989 Apr 06; 159(4):610-5. PubMed ID: 2647859
    [Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE.
    J Infect Dis; 1996 Mar 06; 173(3):731-4. PubMed ID: 8627041
    [Abstract] [Full Text] [Related]

  • 18. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P, Gabutti G, Giammanco G, Dentico P, Moiraghi AR, Ponzio F, Soncini R.
    Vaccine; 2000 Jun 15; 18(25):2796-803. PubMed ID: 10812221
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies.
    Lindberg B, Ahlfors K, Carlsson A, Ericsson UB, Landin-Olsson M, Lernmark A, Ludvigsson J, Sundkvist G, Ivarsson SA.
    Pediatrics; 1999 Jul 15; 104(1):e12. PubMed ID: 10390298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.